Boehringer In­gel­heim plans PhI­II chron­ic kid­ney dis­ease tri­al for al­dos­terone-tar­get­ing drug af­ter mid-stage suc­cess

Boehringer In­gel­heim’s al­dos­terone syn­thase in­hibitor reached the pri­ma­ry end­point of a mid-phase chron­ic kid­ney dis­ease tri­al in com­bi­na­tion with its Eli Lil­ly-part­nered drug Jar­diance. Boehringer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER